• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

DarioHealth touts research on digital therapeutics for diabetes patients

May 27, 2021 By Sean Whooley

DarioHealthDarioHealth (NSDQ:DRIO) announced today that recently published research supports its digital therapeutic platform for type 2 diabetes.

New York-based DarioHealth published a new study through a letter to the editor in the Journal of Diabetes Science and Technology, according to a news release. The study observed participants using DarioHealth’s digital therapeutics for diabetes management, monitoring for both clinical and self-reported impact.

Over three months, participants tracked blood glucose levels in the Dario app and worked with a live certified diabetes care and education specialist (CDCES). The results demonstrated clinically significant improvements in lab test results, platform-based data, and self-reported data, DarioHealth said.

Data published in the letter included a 2% reduction in average HbA1c lab values for participants, a significant reduction in fasting blood glucose (18%) and body mass index (10%), while glucose variability experienced a statistically significant improvement, as did the self-reported evaluation in weight and glucose control satisfaction.

“This clinical study re-confirms the persistent and substantial estimated HbA1c reductions we see in our other studies by demonstrating actual HbA1c reductions,” DarioHealth CMO Dr. Omar Manejwala said in the release. “The present study, while small, demonstrated a robust 2.0% reduction in measured HbA1c along with reductions in glucose variability.”

“These findings add valuable data to the little-understood application of digital self-monitoring and coaching in diabetes management,” added DarioHealth scientific & clinical director Yifat Hershcovitz. “Our findings provide clinical validation for digital self-monitoring to deliver personalized care alongside access to a live coach.  The study demonstrates our data-driven technology is working for people with type 2 diabetes, guiding them in making effective decisions in diabetes management.”

Filed Under: Clinical Trials, Diabetes, Featured, Patient Monitoring, Technology Tagged With: dariohealth

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS